Dayvigo Missed-Dose Protocol: What to Do and How Lemborexant Works

What Is the Dayvigo Missed-Dose Protocol?

Skip the dose if you remember it after you are already in bed and fewer than 7 hours remain before your alarm. Take it at bedtime the following night. No catching up, no splitting, no taking two tablets the next night.

This rule is not arbitrary caution. Lemborexant has an elimination half-life of approximately 17 to 19 hours in adults, meaning meaningful drug concentrations persist well into the next morning even after a single correctly-timed dose. If you take a 10 mg tablet with only 5 or 6 hours until wake-up, residual sedation and next-morning psychomotor impairment become clinically significant. The FDA label specifies that you should not take lemborexant unless you can commit to a full night of sleep of at least 7 hours.

Why Timing Matters More With DORAs Than With Older Sleep Aids

Older sedative-hypnotics like benzodiazepines and Z-drugs work by broadly enhancing GABAergic inhibition. Dual orexin receptor antagonists (DORAs) like lemborexant work by a different mechanism entirely: they block orexin A and orexin B from binding their receptors (OX1R and OX2R), quieting the brain's wakefulness drive rather than forcing sedation. This distinction changes the risk profile of mistimed doses. A broadly sedating drug taken too late may leave you groggy; a DORA taken too late can do the same, plus it may subtly blunt your orexin-mediated alertness during tasks that require it, such as driving.

What to Do in Specific Scenarios

• You forgot and it is still 8 or more hours until wake time. Take the dose now. This counts as a missed dose taken appropriately late, not a skipped dose.
• You are in bed, it is 11 PM, and your alarm is at 5 AM. Six hours remain. Skip the dose. Take your regular dose tomorrow night.
• You took the dose and immediately fell asleep, then woke at 2 AM wondering if you took it. Do not take a second tablet. Assume the first dose was absorbed.
• You are traveling across time zones. Anchor the dose to your new local bedtime, not your home bedtime. Re-synchronize one night at a time.

How Dayvigo Works: The Orexin System Explained

Lemborexant works by switching off the brain's wakefulness signaling, not by sedating you the way alcohol or a benzodiazepine does.

The Orexin Wake-Promotion Circuit

Orexin-producing neurons sit in the lateral hypothalamus. They project widely to the locus coeruleus, tuberomammillary nucleus, raphe nuclei, and basal forebrain, reinforcing wakefulness through norepinephrine, histamine, serotonin, and acetylcholine signaling. People with narcolepsy type 1 lose 85 to 95 percent of these neurons, which is why they cannot stay awake reliably. Insomnia represents the opposite failure: orexin signaling stays hyperactive at night, keeping you alert when you want to sleep.

Lemborexant competitively antagonizes both OX1R and OX2R, the two receptor subtypes through which orexin exerts its arousal effects. By occupying these receptors, it prevents orexin peptides from amplifying wakefulness without forcing global GABAergic suppression. Sleep architecture is therefore better preserved compared to benzodiazepine receptor agonists. In a pharmacodynamic analysis supporting the FDA submission, lemborexant produced dose-dependent reductions in wake after sleep onset (WASO) while maintaining a near-normal proportion of REM and NREM sleep.

SUNRISE-1: The Evidence Base

The SUNRISE-1 trial, published in JAMA Network Open in 2019, was a phase 3, randomized, double-blind, placebo- and active-controlled study in 1,006 adults with insomnia disorder. Participants received lemborexant 5 mg, lemborexant 10 mg, zolpidem extended-release 6.25 mg, or placebo nightly for one month. Both lemborexant doses outperformed placebo on the primary endpoint of subjective sleep onset latency at month 1. Lemborexant 10 mg produced superior next-morning residual sleepiness scores compared with zolpidem extended-release. Approximately 64 percent of enrolled participants were women, a meaningful inclusion rate for a sleep trial, though the published primary analysis did not break efficacy endpoints out by sex.

How the Mechanism Differs From Z-Drugs

| Feature | Zolpidem (Z-drug) | Lemborexant (DORA) | |---|---|---| | Primary target | GABA-A receptor (BZD site) | OX1R and OX2R | | Sleep architecture effect | Suppresses slow-wave and REM | Largely preserves architecture | | Dependence potential | Moderate to high | Lower (Schedule IV, same class) | | Next-morning driving risk | Significant, especially in women | Present but dose-dependent | | Rebound insomnia on stopping | Common | Less common in trials |

Sex-Specific Pharmacokinetics: Why Your Hormonal Status Changes the Equation

Women clear lemborexant differently than men, and your stage of life changes that further.

Why Women Metabolize Lemborexant Differently

Lemborexant is metabolized primarily by CYP3A4. Body composition, CYP enzyme activity, gastrointestinal transit time, and plasma protein binding all differ between female and male biology, and each variable shifts drug exposure. FDA population pharmacokinetic modeling showed that women have approximately 22 percent higher lemborexant exposure (AUC) than men at equivalent doses. The FDA label does not mandate a lower starting dose for women by sex alone, but this difference is the reason why women consistently have higher next-morning impairment rates with sedative-hypnotics as a class, and why the 5 mg starting dose makes clinical sense for most women.

Zolpidem set a precedent here

In 2013, the FDA required manufacturers of zolpidem immediate-release to halve the recommended dose for women from 10 mg to 5 mg, and for extended-release from 12.5 mg to 6.25 mg, after pooled data confirmed women had double the next-morning blood concentrations of men. Lemborexant did not receive a sex-stratified label update at approval, but the underlying PK difference is real and clinicians should start women at 5 mg.

Across the Reproductive Life Stages

Reproductive years (ages roughly 18 to 40). Insomnia in this group is often tied to the menstrual cycle. Progesterone rises in the luteal phase and has mild sedating properties through GABA-A modulation. Premenstrual insomnia, by contrast, is driven by the progesterone withdrawal that precedes menstruation. Lemborexant has not been studied in a cycle-specific design, so whether dosing should be adjusted across cycle phases is unknown. Starting at 5 mg and titrating based on response remains the clinical standard.

PCOS. Women with polycystic ovary syndrome have a significantly elevated prevalence of sleep-disordered breathing and insomnia. A systematic review in Fertility and Sterility found sleep disturbance in 40 to 80 percent of women with PCOS, driven by insulin resistance, hyperandrogenism, and elevated BMI. Lemborexant has not been studied specifically in PCOS populations. Treating insomnia in PCOS without first ruling out obstructive sleep apnea is a clinical mistake: if OSA is present, a sedative-hypnotic may worsen nocturnal hypoxemia.

Perimenopause. This is the life stage where insomnia rates climb most sharply in women. The Study of Women's Health Across the Nation (SWAN) documented that difficulty sleeping affects up to 61 percent of perimenopausal women, compared with roughly 40 percent of premenopausal women. Hot flashes fragment sleep architecture directly. Lemborexant targets the orexin pathway rather than thermoregulation, so it addresses the arousal component of perimenopausal insomnia but does not reduce vasomotor symptoms. For women whose insomnia is primarily hot flash-driven, menopausal hormone therapy or a non-hormonal vasomotor agent addresses the root cause in a way lemborexant cannot.

Post-menopause. CYP3A4 activity declines modestly with age, which may slow lemborexant clearance further. Older women are also at higher risk of falls from residual next-morning sedation. The 5 mg dose is the preferred starting point in women over 65, and the 10 mg dose should be used only after confirming the lower dose provides insufficient benefit and causes no morning impairment.

Pregnancy and Lactation: What You Need to Know

Lemborexant is not recommended during pregnancy. Animal reproductive studies showed fetal harm at doses producing exposures lower than the maximum recommended human dose. Human data are absent. The FDA prescribing information classifies the pregnancy data as inadequate to establish safety.

Pregnancy

Orexin signaling appears to play a role in fetal brain development, which is one reason why DORA use in pregnancy is approached with caution. FDA labeling for lemborexant states that available animal data show adverse developmental effects and that there are no adequate and well-controlled studies in pregnant women. If you are pregnant and struggling with insomnia, cognitive behavioral therapy for insomnia (CBT-I) is the first-line intervention recommended by ACOG regardless of trimester, and carries no fetal risk.

If you are trying to conceive, discuss timing with your prescriber. Lemborexant is not classified as a known teratogen with a specific washout requirement, but given the absence of human safety data, most clinicians recommend stopping the drug before attempting conception.

Lactation

Lemborexant transfer into human breast milk has not been studied. CNS-active drugs that are highly lipophilic tend to transfer into milk at measurable concentrations. Because neonates and infants have immature CYP enzyme systems and cannot clear CNS depressants efficiently, the FDA label advises against use during breastfeeding. If postpartum insomnia is severe and non-pharmacologic measures have failed, a shared decision-making conversation about whether to pause breastfeeding or choose a drug with a more established lactation profile is appropriate.

Contraception Requirements

No specific contraception mandate appears in the FDA label for lemborexant, unlike true teratogens such as isotretinoin or thalidomide. Women of reproductive potential who are prescribed lemborexant should nonetheless use reliable contraception, given the absence of human pregnancy safety data and the theoretical concern about orexin pathway modulation during organogenesis.

Who This Is Right For, and Who Should Think Twice

Women Who May Benefit Most

• Adults with chronic insomnia disorder characterized by both difficulty falling asleep and difficulty staying asleep (sleep onset and sleep maintenance subtypes).
• Women who have tried CBT-I and need adjunctive pharmacotherapy.
• Perimenopausal women with arousal-type insomnia not driven primarily by hot flashes.
• Women who experienced significant next-morning grogginess or dependence concerns on Z-drugs.
• Women with a history of depression: unlike some benzodiazepine receptor agonists, DORAs do not carry a boxed warning for complex sleep behaviors in all cases (the 2019 FDA complex sleep behavior warning applies across sedative-hypnotics as a class, but lemborexant's risk profile is mechanistically distinct).

Women Who Should Be Cautious or Avoid Lemborexant

• Pregnant women or those actively trying to conceive. Avoid.
• Breastfeeding women. Avoid unless weaning or alternative.
• Women with narcolepsy. Blocking orexin in someone with an already-depleted orexin system carries obvious risk.
• Women with severe hepatic impairment. CYP3A4 metabolism is impaired; drug accumulates.
• Women taking strong CYP3A4 inhibitors (fluconazole, clarithromycin, certain HIV antiretrovirals). Concomitant use is contraindicated or requires dose reduction per the FDA label.
• Women with untreated obstructive sleep apnea. Treat OSA first, because sedative-hypnotics may worsen nocturnal hypoxemia.

A practical decision framework for lemborexant in women by life stage:

| Life Stage | First Consider | Lemborexant Role | |---|---|---| | Reproductive (cycling) | CBT-I, sleep hygiene | Second-line if CBT-I fails | | PCOS | Rule out OSA first | Adjunct only after OSA addressed | | TTC / pregnancy | CBT-I only | Avoid | | Postpartum / lactating | CBT-I, sleep consolidation strategies | Avoid | | Perimenopause | HRT or non-hormonal vasomotor Rx if hot flash-driven | Concurrent if arousal-type component persists | | Post-menopause | CBT-I, then pharmacotherapy | Start at 5 mg; fall-risk assessment required |

Drug Interactions Particularly Relevant to Women

Women are prescribed more CNS-active drugs than men and are more likely to be on medications that interact with CYP3A4. This matters for lemborexant in practice.

CYP3A4 Inhibitors

Strong inhibitors increase lemborexant exposure substantially. The FDA label contraindicates co-administration with strong CYP3A4 inhibitors. Moderate inhibitors such as fluconazole (commonly used for vaginal candidiasis) require the lemborexant dose to be capped at 5 mg for the duration of the course. Women who regularly use azole antifungals for recurrent vulvovaginal candidiasis should discuss this interaction with their prescriber.

Hormonal Contraceptives

Combined oral contraceptives induce or inhibit various CYP isoforms depending on their progestin component. The clinical significance of this interaction with lemborexant has not been directly studied. Until data exist, this represents an evidence gap you should discuss with your prescriber, particularly if you are starting or stopping hormonal contraception.

Alcohol and Cannabis

Both produce additive CNS depression with lemborexant. The FDA label explicitly warns against combining lemborexant with alcohol. Cannabis use is common among women with insomnia; cannabis and lemborexant have not been studied in combination, but the interaction is expected to be additive and could prolong next-morning impairment.

Stopping Lemborexant: What to Expect

Unlike benzodiazepines, lemborexant does not require a formal taper in most patients. In the SUNRISE-2 trial, which evaluated 12 months of nightly lemborexant use followed by a 2-week double-blind withdrawal, rebound insomnia rates were low and comparable to placebo. This is mechanistically consistent with the DORA class: because lemborexant does not down-regulate GABA-A receptors, the physical withdrawal phenomenon seen with benzodiazepines is absent.

Psychological dependence on any sleep aid is possible. Women with anxiety disorders, which are more prevalent in women than men, may be at higher psychological dependence risk. CBT-I during or after a course of lemborexant remains the strategy most likely to produce durable sleep improvement after stopping the drug.

Frequently Asked Questions